Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | CTSC | P53634 | 2/20 | 0.49 |
| ▸ | ACACB | O00763 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27710873 | 1.00 | NPC1 (0.58) | NPC1RAB9AMMP2LMNAKMT2A | |
| SCHEMBL31633415 | 0.99 | NPC1 (0.59) | NPC1RAB9AMMP2LMNAKMT2A | |
| SCHEMBL14345777 | 0.88 | NPC1 (0.69) | NPC1RAB9AMMP2LMNAKMT2A | |
| SCHEMBL24642659 | 0.87 | NPC1 (0.59) | NPC1RAB9ALMNAKMT2AALDH1A1 | |
| SCHEMBL13866374 | 0.83 | HPGD (0.54) | MMP2LMNACTSC | |
| SCHEMBL29630808 | 0.83 | MMP2 (0.55) | MMP2LMNACTSCNPSR1 | |
| SCHEMBL2032499 | 0.81 | MMP2 (0.56) | MMP2LMNACTSCNPSR1 | |
| SCHEMBL2032501 | 0.81 | MMP2 (0.56) | MMP2LMNACTSCNPSR1 | |
| SCHEMBL16983210 | 0.81 | MMP2 (0.56) | MMP2LMNACTSCNPSR1 | |
| SCHEMBL13448351 | 0.80 | NPC1 (0.51) | NPC1RAB9ALMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2012-05-10 | — | — | US | disclosed |
| EP-1644019-B1 | ABUSE RESISTANT AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723305-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100105781-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | SHIRE LLC (US) | 2010-04-29 | — | — | US | disclosed |
| US-7700561-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-04-20 | — | — | US | disclosed |
| US-7687466-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687467-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7678771-B2 | Abuse-resistant amphetamine prodrugs | SHIRE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090131334-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131533-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131325-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131322-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131526-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | SHIRE LLC (US) | 2009-05-14 | — | — | US | disclosed |
| US-7375083-B2 | Pharmaceutical compositions for prevention of overdose or abuse | SHIRE LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20080086016-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | NEW RIVER PHARMACEUTICALS INC. (US) | 2008-04-10 | — | — | US | disclosed |
| US-7223735-B2 | Abuse resistant lysine amphetamine compounds | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | NEW RIVER PHARMACEUTICALS INC. (US) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131533-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20090131322-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20100105781-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | COMT, KDM6B, KDM5B | NPC1 137/4885RAB9A 2367/4885MMP2 2188/4885 |
| US-20070042955-A1 | Abuse-resistant amphetamine prodrugs | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20090131526-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20120115950-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20100197798-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20090131325-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20080086016-A1 | ABUSE RESISTANT LYSINE AMPHETAMINE COMPOUNDS | COMT, KDM6B, KDM5B | NPC1 137/4885RAB9A 2367/4885MMP2 2188/4885 |
| US-20090124831-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20090131334-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
| US-20110009669-A1 | ABUSE-RESISTANT AMPHETAMINE PRODRUGS | COMT, CYP3A5, CYP2D6 | NPC1 119/4885RAB9A 2485/4885MMP2 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.